Forte Total Other Income Expense Net from 2010 to 2024

FBRX Stock  USD 19.79  3.11  18.65%   
Forte Biosciences Total Other Income Expense Net yearly trend continues to be fairly stable with very little volatility. Total Other Income Expense Net is likely to outpace its year average in 2024. During the period from 2010 to 2024, Forte Biosciences Total Other Income Expense Net regression line of annual values had r-squared of  0.1 and arithmetic mean of (233,056). View All Fundamentals
 
Total Other Income Expense Net  
First Reported
2017-03-31
Previous Quarter
307 K
Current Value
237 K
Quarterly Volatility
5.9 M
 
Covid
Check Forte Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Forte Biosciences' main balance sheet or income statement drivers, such as Interest Income of 1.3 M, Depreciation And Amortization of 8.6 K or Interest Expense of 14.5 K, as well as many indicators such as Price To Sales Ratio of 9.98, Dividend Yield of 0.0 or PTB Ratio of 0.7. Forte financial statements analysis is a perfect complement when working with Forte Biosciences Valuation or Volatility modules.
  
Check out the analysis of Forte Biosciences Correlation against competitors.
For more information on how to buy Forte Stock please use our How to Invest in Forte Biosciences guide.

Latest Forte Biosciences' Total Other Income Expense Net Growth Pattern

Below is the plot of the Total Other Income Expense Net of Forte Biosciences over the last few years. It is Forte Biosciences' Total Other Income Expense Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Forte Biosciences' overall financial position and show how it may be relating to other accounts over time.
Total Other Income Expense Net10 Years Trend
Slightly volatile
   Total Other Income Expense Net   
       Timeline  

Forte Total Other Income Expense Net Regression Statistics

Arithmetic Mean(233,056)
Geometric Mean188,564
Coefficient Of Variation(334.67)
Mean Deviation512,111
Median(102,000)
Standard Deviation779,975
Sample Variance608.4B
Range2.9M
R-Value0.31
Mean Square Error591.3B
R-Squared0.1
Significance0.26
Slope54,446
Total Sum of Squares8.5T

Forte Total Other Income Expense Net History

20241.1 M
2023M
202217 K
2021-222 K
2020-205 K
2019 -4333.0
2018-1.4 M

About Forte Biosciences Financial Statements

Forte Biosciences investors use historical fundamental indicators, such as Forte Biosciences' Total Other Income Expense Net, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Forte Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Other Income Expense NetM1.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Forte Stock Analysis

When running Forte Biosciences' price analysis, check to measure Forte Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forte Biosciences is operating at the current time. Most of Forte Biosciences' value examination focuses on studying past and present price action to predict the probability of Forte Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Forte Biosciences' price. Additionally, you may evaluate how the addition of Forte Biosciences to your portfolios can decrease your overall portfolio volatility.